SAMSUNG EPIS HOLDINGS Co., Ltd.
Financials
Valuation Metrics
SAMSUNG EPIS HOLDINGS Co., Ltd.'s Market Cap is ₩9.6T. Ranked #68 of 2,436 in KR market (top 3%), #65 of 787 on KOSPI (top 8%), #4 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 9.60T KRW | KR#68/2,436 Sec#4/234 |
| Revenue | 251.69B KRW | KR#901/2,436 Sec#46/234 |
| Net Income | 85.31B KRW | KR#244/2,436 Sec#14/234 |
| Total Assets | 7.72T KRW | KR#133/2,436 Sec#3/234 |
| Net Assets | 5.91T KRW | KR#86/2,436 Sec#3/234 |
| Value | ||
| P/E | 112.58x | KR#1,448/2,436 Sec#96/234 |
| P/B | 1.63x | KR#1,841/2,436 Sec#132/234 |
| P/S | 38.16x | KR#2,360/2,436 Sec#194/234 |
| FCF Yield | -1.15% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 1.44% | KR#1,380/2,436 Sec#96/234 |
| ROA | 1.11% | KR#1,293/2,436 Sec#92/234 |
| Op. Margin | -25.29% | KR#2,162/2,436 Sec#148/234 |
| Financial Health | ||
| Debt Ratio | 30.64% | KR#98/2,436 Sec#13/234 |
| Total Debt | 377.00B KRW | KR#348/2,436 Sec#13/234 |
| FCF | -110.08B KRW | KR#2,148/2,436 Sec#213/234 |
| Cash | 131.30B KRW | KR#383/2,436 Sec#16/234 |
| Current Ratio | 1.36x | KR#1,422/2,436 Sec#150/234 |
| Performance | ||
| 1M Return | -7.32% | KR#1,602/2,436 Sec#155/234 |
| From 52W High | -50.06% | KR#1,202/2,436 Sec#100/234 |
| 1Y MDD | -53.03% | KR#1,059/2,436 Sec#87/234 |
| Trading | ||
| Volume | 28,355 shares | KR#1,720/2,436 Sec#163/234 |
| Foreign Own. | 6.77% | KR#645/2,436 Sec#62/234 |
| Per Share | ||
| EPS | 21,211 KRW | KR#31/2,436 Sec#2/234 |
| BPS | 241,829 KRW | KR#46/2,436 Sec#1/234 |
Company Info
Samsung Episholdings is a bio investment holding company established in 2025, spun off from Samsung Biologics, and is engaged in biotechnology platform development. The company plans to intensively foster new businesses by leveraging its experience in growing its subsidiary, Samsung Bioepis, into a global top 5 biosimilar development company within 10 years through an R&D-focused biotech strategy. Samsung Bioepis has successfully developed and launched 11 biosimilar products, the most worldwide, demonstrating successful biosimilar development and commercialization. The company is headquartered in Yeonsu-gu, Incheon.